Semaglutide Use in Diabetes Doubles Risk of Irreversible Vision Loss, claims study
Researchers have established that the application of once-weekly semaglutide in patients with type 2 diabetes (T2D) increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION). A recent study was conducted by Jakob G. and colleagues which was published in the International Journal of Retina and Vitreous.
The primary aim of this study was to prospectively evaluate the risk of NAION in people with T2D exposed to semaglutide compared with those who were not, by employing a strong longitudinal cohort design.
This was a five-year longitudinal cohort study (2018–2024) which identified all individuals with T2D in Denmark (n = 424,152). The cohort was stratified into two groups:
• Semaglutide exposure group: 106,454 people who were dispensed once-weekly semaglutide.
• Non-exposure group: 317,698 people who did not receive semaglutide.
The incidence rates and HRs of NAION were evaluated using a multivariable Cox proportional hazards regression model. Observations included a total of 1,915,120 person-years.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.